The findings, published in the April issue of AIDS Research and Human Retroviruses, could pave the way for the use of such peptides in gene therapy using HIV-based vectors as the delivery method.
"Although it may seem counterintuitive to value or even study a peptide that increases the ability of HIV-1 to enter a broad range of human cells, retroviral vectors are currently being explored as vehicles for gene therapy," the authors wrote. "In this area, at least, agents that enhance retroviral uptake could contribute to an emerging field of medicine."
"So many people have tried to deliver genes into different kinds of cells," said study co-author Shen Pang, adjunct associate professor at the UCLA School of Dentistry and a member of the UCLA AIDS Institute. "If you know of some method that can enhance gene delivery, you would have a useful tool."
Retrocyclin-1 (RC-100) is a circular peptide that has been shown in previous studies to inhibit the infection of CD4 cells with HIV. RC-111 is also cyclic and has the same amino acid sequence as retrocyclin-1. In both peptides, the amino acids are strung like 18 beads along the molecule's backbone. The amino acids in RC-111, however, are in reverse order.
The researchers had initially wanted to quantify previous research by Dr. Robert I. Lehrer, distinguished professor of medicine in the division of infectious diseases at the David Geffen School of Medicine at UCLA and a co-author of the present study. Unexpectedly, the researchers discovered that while retrocyclin-1 inhibited infection of CD4 cells with HIV-1 by about 95 percent, the RC-111 variant enhanced viral infection five-fold.
There are three structural varieties of peptid
Source:University of California - Los Angeles